Last reviewed · How we verify
NCT04792658
Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation
trial testing Detailed interview with personal demographic data in Psychiatric Disorder in 100 participants. Status unknown.
20 June 2022
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 10 March 2021 |
| Primary completion | 20 June 2022 |
| Estimated completion | 20 September 2023 |
Drugs / interventions tested
- Detailed interview with personal demographic data
- Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)
- The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)
- the Hamilton Depression Rating Scale
- The Hamilton Anxiety Rating Scale
- The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)
Conditions studied
- Psychiatric Disorder — all drugs for Psychiatric Disorder →
- Benzodiazepine-Related Disorders — all drugs for Benzodiazepine-Related Disorders →
Sponsor
Assiut University
Who can join
Adults 18 to 50, any sex, with Psychiatric Disorder or Benzodiazepine-Related Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction. previous study reported that The results of the study are important in that they corroborate the mounting evidence that a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal. The findings highlight the residual neurocognitive compromise associated with long-term benzodiazepine therapy as well as the important clinical implications of these results.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04792658
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Psychiatric Disorder
Currently open trials in the same condition.
- NCT07282158 — Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians · NA · recruiting
- NCT06977503 — Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers · NA · recruiting
- NCT07354633 — Full Sail Ahead, Sailing in Psychosocial Rehabilitation. · NA · recruiting
- NCT07053098 — External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting · NA · recruiting
- NCT06376734 — Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness · Phase 2 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04792658 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 11 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04792658.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing